



NEW CATALOGUE PRODUCT

VALSYNTHESE ANNOUNCES "APMN (CAS 438056-69-0)"

APMN, 4-(4'-aminophenyl)-morpholin-3-one, the key intermediate for Rivaroxaban (2.5 mg), a worldwide produced blood thinner, is now part of our catalogue product portfolio. Valsynthese SA has recently launched a strategic investment in hydrogenation, of which APMN is one of the key products.

The new hydrogenation facilities, both supporting a pressure of max 25 bar, are represented by:

- a state-of-the-art kilo-lab (ISO/GMP)
- a pilot-plant facility (up to 7 bar)
- a 4000 L Hastelloy new reactor (ISO/GMP) planned for 2023

Watch the video and discover the new products.



Société Suisse des Explosifs Group

